Targets › EFNB2
2 programs from 2 companies in 4 trials: 3 Phase 2, 1 Phase 1; Oncology, Immunology; next expected readout Dec 2028.
Cell surface transmembrane ligand for Eph receptors, a family of receptor tyrosine kinases which are crucial for migration, repulsion and adhesion during neuronal, vascular and epithelial development. Binds promiscuously Eph receptors residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. (UniProt, P52799)
Open in Phaseline: the race on EFNB2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Mediar Therapeutics | MTX-474 anti-EphrinB2 monoclonal antibody | EFNB2 | Phase 2 | Diffuse Cutaneous Systemic Sclerosis | Dec 2028 |
| Vasgene Therapeutics | SEphB4-HSA Ephrin-B2 inhibitor | EFNB2 | Phase 2 | Muscle-Invasive Bladder Carcinoma; Stage IV Bladder Urothelial Carcinoma; Head and Neck Squamous Cell Carcinoma | Sep 2029 |
Muscle-Invasive Bladder Carcinoma (1) Stage IV Bladder Urothelial Carcinoma (1) Head and Neck Squamous Cell Carcinoma (1) Diffuse Cutaneous Systemic Sclerosis (1)
mixed (1), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.